Humedix Co

Humedix Co EBITDA per Employee

The EBITDA per Employee of Humedix Co (200670.KQ) as of Oct 23, 2026 is 125.23 M KRW. In the previous year, EBITDA per Employee was 133.04 M KRW — a change of -5.86% (lower).

EBITDA per Employee

125.23 MKRW

YoY

-5.86%

Last updated:

EBITDA per Employee of Humedix Co is 2025 125.23 M KRW. EBITDA per Employee of Humedix Co was 2024 133.04 M KRW. It decreases by -5.86% lower compared to the previous year.

The Humedix Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
32.80 M KRW
Jan 1, 2019
38.73 M KRW
Jan 1, 2020
52.86 M KRW
Jan 1, 2021
45.72 M KRW
Jan 1, 2022
105.04 M KRW
Jan 1, 2023
115.42 M KRW
Jan 1, 2024
133.04 M KRW
Jan 1, 2025
125.23 M KRW
The Humedix Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
125.23 MKRW-5.86%
133.04 MKRW+15.26%
115.42 MKRW+9.89%
105.04 MKRW+129.72%
45.72 MKRW-13.49%
52.86 MKRW+36.49%
38.73 MKRW+18.07%
32.80 MKRW-12.80%
37.61 MKRW+10.47%
34.05 MKRW-18.84%
41.96 MKRW+75.68%
23.88 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humedix Co Stock analysis

What does Humedix Co do? Humedix Co Ltd, identified by the ticker symbol 200670.KQ and ISIN KR7200670008, is a South Korean enterprise operating within the health care sector, specifically in the pharmaceuticals industry. Headquartered in Seongnam, the company has established itself as a specialized manufacturer and distributor of medical devices and therapeutic products. The firm's core business activities revolve around the production and sale of hyaluronic acid-based medical devices, which are widely utilized in various clinical applications, as well as specialized products designed for the treatment of arthritis. This focus on hyaluronic acid highlights the company's commitment to addressing significant health challenges related to joint health and mobility, catering to a growing demographic concerned with degenerative joint conditions. The company maintains a workforce of 338 full-time employees, reflecting its operational scale and capacity to manage both domestic and international supply chains. Humedix achieved a significant milestone in its corporate history by conducting its initial public offering on December 26, 2014. This event marked the company's entry into the public markets, providing it with increased visibility and access to capital for potential expansion and research initiatives. Since its public listing, Humedix has continued to refine its product portfolio and strengthen its market presence. Geographically, the company distributes its products not only within the domestic South Korean market but also extends its reach to overseas markets. This dual-market strategy allows Humedix to diversify its revenue streams and mitigate risks associated with regional economic fluctuations. By serving both local and international customers, the company leverages its manufacturing capabilities to meet diverse regulatory and consumer demands across different regions. The headquarters in Seongnam serves as the central hub for its administrative, research, and distribution operations, ensuring efficient coordination of its business activities. Through its dedicated efforts in developing hyaluronic acid-based solutions, Humedix Co Ltd continues to play a role in the broader health care ecosystem, providing essential medical devices and treatments that improve patient outcomes. The company's website, http://www.humedix.com/, serves as a primary resource for stakeholders seeking further information about its products, corporate governance, and financial performance. As the health care landscape evolves, Humedix remains focused on its core competencies in pharmaceutical manufacturing and medical device distribution, aiming to sustain growth and innovation in its specialized field. Humedix Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humedix Co stock

EBITDA per Employee of Humedix Co is 125.23 M KRW in 2025.

EBITDA per Employee of Humedix Co changed from 133.04 M KRW to 125.23 M KRW, representing a -5.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Humedix Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Humedix Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Humedix Co

All Key Metrics — Humedix Co